- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NMR of America's sales climb, net falls
Imaging services firm NMR of America posted higher revenues forits 1996 fiscal year (end-March), but the firm's net income slippeda bit as a result of a higher tax rate. The Murray Hill, NJ, company posted revenues of $23.8 millionfor the year,
Imaging services firm NMR of America posted higher revenues forits 1996 fiscal year (end-March), but the firm's net income slippeda bit as a result of a higher tax rate.
The Murray Hill, NJ, company posted revenues of $23.8 millionfor the year, compared with $18 million the year before. NMR ofAmerica said that the higher numbers were due to several acquisitionsmade last year, including five Florida centers acquired throughits purchase of Morgan Medical Holdings.
NMR of America's net income for the year fell from $2.4 millionin 1995 to $1.8 million. The company said that pre-tax earningsfor the most recent year were at the highest level in the company'shistory, but net income was lower because the 1995 results reflectthe benefits of a lower tax rate.
NMR of America is involved in merger discussions with MedicalResources (SCAN 5/22/96). The companies said last month that theyhave completed due diligence investigations and are moving forwardwith the merger.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
